Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Liquidia Corporation (NASDAQ: LQDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation focused on biopharmaceutical products for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), Liquidia uses these filings to report financial results, material agreements, governance changes and other significant events.
Investors can review Forms 10‑K and 10‑Q for detailed discussions of Liquidia’s business, including its PRINT® technology platform, the commercialization of YUTREPIA™ (treprostinil) inhalation powder, development of the investigational L606 treprostinil liposome inhalation suspension, and promotion of generic Treprostinil Injection under a profit‑sharing agreement with Sandoz. These periodic reports typically include segment information, research and development spending, risk factors related to PAH and PH‑ILD markets, and descriptions of key contracts.
Current reports on Form 8‑K highlight specific events such as quarterly earnings releases, financing transactions under the revenue interest financing agreement with HealthCare Royalty Partners IV, L.P. (HCR), entry into the exclusive license with Vectura for the nebulizer device used with L606, leases for expanded manufacturing facilities in Morrisville, North Carolina, and outcomes of annual stockholder meetings. Other 8‑K filings may document executive appointments, compensation arrangements and other governance matters.
Users can also monitor proxy statements and Form 4 insider transaction reports to understand board elections, advisory votes on executive compensation and equity awards to officers and directors. Stock Titan’s interface combines these documents with AI‑powered summaries that explain complex sections of long filings, highlight key changes from prior periods and help clarify how new agreements, clinical developments or financing structures may affect Liquidia’s operations and capital structure.
With real‑time updates from EDGAR and structured access to historical filings, this page serves as a central resource for analyzing Liquidia’s regulatory history, capital markets activity and disclosures related to its treprostinil‑based therapies for PAH and PH‑ILD.
Raman Singh, a director of Liquidia Corporation (LQDA), reported a sale of common stock. The Form 4 shows a transaction dated 09/03/2025 where the reporting person sold 7,500 shares at a price of $29.42 each, leaving 31,255 shares beneficially owned after the sale. The filing notes the total includes 18,396 restricted stock units granted on June 17, 2025 that have not vested as of the Form 4 date. The Form 4 is signed by Raman Singh on 09/05/2025.
Liquidia Corporation (LQDA) filed a Form 144 disclosing a proposed sale of 7,500 common shares with an aggregate market value of $220,650. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 09/03/2025. The securities were acquired as Restricted Stock Units from Liquidia Corporation on 06/16/2025, and the filing reports payment/vesting on that same date. The filing shows 86,091,454 shares outstanding. The form indicates no securities sold by the same person in the past three months. Several standard filer and issuer contact fields in the submitted tables appear blank.
Scott Moomaw, Chief Commercial Officer of Liquidia Corporation (LQDA), reported multiple equity transactions. On 08/29/2025 he received 1,875 restricted stock units (RSUs) that convert one-for-one into common shares, increasing his RSU holdings. On 09/02/2025 he sold a total of 70,692 shares in three transactions: 692 shares at $29.05 and 8,315 plus 61,685 shares at a volume-weighted average price of $28.6224. The Form 4 notes the sales were effected pursuant to Rule 10b5-1 trading plans and some shares were sold to cover taxes related to RSU settlements. Following these transactions he beneficially owned 155,254 common shares (direct).
Russell Schundler, General Counsel of Liquidia Corporation (LQDA), reported multiple transactions in company equity. On 08/29/2025, 2,344 restricted stock units (RSUs) vested and converted into 2,344 shares. On 09/02/2025, 1,063 shares were sold at $29.05 per share under a Rule 10b5-1 plan to cover taxes related to RSU settlement. After these transactions, Schundler beneficially owned 580,098 shares directly and 14,500 shares indirectly (by spouse), for a total of 594,598 shares reported. The filing notes multiple prior RSU grants (2022, 2023, 2024, 2025) with portions unvested and 11,869 shares held under the employee stock purchase plan.
Liquidia Corporation insider Sarah Krepp, Chief Human Resource Officer, reported a small disposition of company common stock under a Rule 10b5-1 trading plan. The Form 4 shows a sale on 08/29/2025 of 209 shares at $29.05 per share, executed pursuant to a 10b5-1 plan adopted December 15, 2023, and the transaction was to cover taxes on RSU settlements. After the sale, Krepp beneficially owns 143,130 shares, including multiple unvested RSU tranches (specified amounts) and 5,312 shares from the 2020 Employee Stock Purchase Plan.
Michael Kaseta, Chief Financial Officer and Chief Operating Officer of Liquidia Corporation (LQDA), reported equity transactions in a Form 4. On 08/29/2025 he had 2,344 restricted stock units (RSUs) convert into common stock, increasing his beneficial ownership to 359,596 shares. Pursuant to a Rule 10b5-1 plan, he sold 1,148 shares on 09/02/2025 at $29.05 per share to cover taxes, leaving 358,448 shares beneficially owned. The filing details prior RSU grants: a 37,500 RSU grant on 01/16/2022 of which 32,813 had vested, multiple grants in 2023–2025 with substantial unvested RSU balances, and 11,257 shares held under the 2020 Employee Stock Purchase Plan.
Liquidia Corp Chief Accounting Officer Dana Boyle reported a transaction under a Rule 10b5-1 plan: on 08/29/2025 she sold 296 shares of common stock at $29.05 per share to cover tax withholding related to vested restricted stock units. Following the sale, Boyle beneficially owns 186,649 shares, which include multiple unvested RSU grants from 2022 through 2025 and 11,869 shares acquired under the 2020 Employee Stock Purchase Plan. The filing is a Form 4 and was signed on 09/03/2025.
Paul B. Manning, a director of Liquidia Corp (LQDA), reported multiple sales of Common Stock in late August and early September 2025. The Form 4 shows sales on 08/28/2025 (154,337 shares at a weighted average $27.94), 08/29/2025 (188,232 shares at $27.62 weighted average), and two sales on 09/02/2025 (254,038 shares at $28.67 weighted average and 74,230 shares at $29.14 weighted average). The filing lists several holdings held indirectly through trusts and entities (including PBM 2024 GRAT, PBM 2000 Trust, BKB Growth Investments, PBM Capital Finance, and PD Joint Holdings) and notes 3,131,794 shares disposed of in total on one line and various indirect ownership amounts disclosed in footnotes.
Insider transactions by Jason Adair, Chief Business Officer of Liquidia Corporation (LQDA). The Form 4 reports vesting and sales of restricted stock units (RSUs) and open-market sales made under Rule 10b5-1 plans. On 07/11/2025 Mr. Adair had 3,906 RSUs converted to common stock. Subsequent sales: 26,057 shares sold on 08/28/2025 at a VWAP of $27.8564 and 451 shares sold on 09/02/2025 at $29.05. A 1,562-share RSU conversion occurred on 08/29/2025. The filing discloses total beneficial ownership adjustments including unvested RSU balances from grants dated 01/11/2023, 07/06/2023, 01/11/2024 and 01/11/2025 and 10,746 shares from the 2020 ESPP; corrected prior filing counts are also noted.
Dr. Rajeev Saggar, Chief Medical Officer of Liquidia Corporation (LQDA), reported a sale of 20,000 shares of common stock on 08/28/2025. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2025 and produced a volume-weighted average price of $27.8536 (prices on the day ranged from $27.22 to $28.53). After the transaction, Dr. Saggar beneficially owned 249,727 shares, which include multiple unvested restricted stock unit (RSU) grants totaling 138,356 unvested RSUs from grants dated January 11, 2023, 2024 and 2025, plus 7,131 shares acquired under the company ESPP. The Form 4 is signed by Dr. Saggar on 09/02/2025.
FAQ
What is the current stock price of Liquidia Corporation (LQDA)?
What is the market cap of Liquidia Corporation (LQDA)?
